Adial Pharmaceuticals, Inc (ADIL): Price and Financial Metrics
ADIL Price/Volume Stats
| Current price | $2.86 | 52-week high | $15.00 |
| Prev. close | $3.12 | 52-week low | $2.44 |
| Day low | $2.70 | Volume | 65,900 |
| Day high | $3.00 | Avg. volume | 67,612 |
| 50-day MA | $4.38 | Dividend yield | N/A |
| 200-day MA | $7.14 | Market Cap | 3.48M |
ADIL Stock Price Chart Interactive Chart >
Adial Pharmaceuticals, Inc (ADIL) Company Bio
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders in the United States. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis. The company was founded in 2010 and is based in Charlottesville, Virginia.
Latest ADIL News From Around the Web
Below are the latest news stories about ADIAL PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ADIL as an investment opportunity.
Adial Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceCHARLOTTESVILLE, Va., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that Cary Claiborne, CEO of Adial Pharmaceuticals, will be participating in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 at the Lotte New York Palace Hotel |
Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss the Need for New Alcohol Use Disorder Treatments at the European Society for Biomedical Research on AlcoholismCHARLOTTESVILLE, Va., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that the Chief Medical Officer of Adial, Bankole Johnson, D.SC., M.D., and Key Opinion Leaders Jonathan Chick, M.D., Hannu Alho, M.D., Otto Lesch, M.D., and Giovanni Addolorato, M.D., will be presenting at |
Adial Pharmaceuticals Regains Compliance with Nasdaq Listing RequirementsCHARLOTTESVILLE, Va., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it received notice from Nasdaq on August 21, 2023 that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). Nasdaq determined that for |
Adial Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business UpdateReported Positive Feedback from US and EU Regulatory Meetings Sale of Purnovate Significantly Reduces Cash Burn Rate Charlottesville, Va., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the second quarter of 2023. Cary |
Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement and Reduce the Public FloatCommon Stock Will Begin Trading on Split-Adjusted Basis on August 7, 2023CHARLOTTESVILLE, Va., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will effect a 1-for-25 reverse stock split (“reverse split”) of its common stock, par value $0.001 per share (“Common Stock”) |
ADIL Price Returns
| 1-mo | -18.17% |
| 3-mo | -45.05% |
| 6-mo | -67.31% |
| 1-year | -69.90% |
| 3-year | -91.89% |
| 5-year | -95.80% |
| YTD | -46.79% |
| 2022 | -92.04% |
| 2021 | 58.82% |
| 2020 | -29.46% |
| 2019 | -52.93% |
| 2018 | N/A |
Loading social stream, please wait...